HRP20100521T1 - Monoklonska antitijela protiv čimbenika rasta hepatocita - Google Patents

Monoklonska antitijela protiv čimbenika rasta hepatocita Download PDF

Info

Publication number
HRP20100521T1
HRP20100521T1 HR20100521T HRP20100521T HRP20100521T1 HR P20100521 T1 HRP20100521 T1 HR P20100521T1 HR 20100521 T HR20100521 T HR 20100521T HR P20100521 T HRP20100521 T HR P20100521T HR P20100521 T1 HRP20100521 T1 HR P20100521T1
Authority
HR
Croatia
Prior art keywords
hgf
monoclonal antibody
mab
inhibits
binding
Prior art date
Application number
HR20100521T
Other languages
English (en)
Croatian (hr)
Inventor
Jin Kim Kyung
Su Yi-Chi
Original Assignee
Galaxy Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35320045&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20100521(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Galaxy Biotech filed Critical Galaxy Biotech
Publication of HRP20100521T1 publication Critical patent/HRP20100521T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
HR20100521T 2004-04-15 2010-09-22 Monoklonska antitijela protiv čimbenika rasta hepatocita HRP20100521T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/825,060 US20040208876A1 (en) 2003-04-18 2004-04-15 Monoclonal antibodies to hepatocyte growth factor
PCT/US2004/026565 WO2005107800A1 (en) 2004-04-15 2004-08-13 Monoclonal antibodies to hepatocyte growth factor

Publications (1)

Publication Number Publication Date
HRP20100521T1 true HRP20100521T1 (hr) 2010-10-31

Family

ID=35320045

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20100521T HRP20100521T1 (hr) 2004-04-15 2010-09-22 Monoklonska antitijela protiv čimbenika rasta hepatocita

Country Status (26)

Country Link
US (5) US20040208876A1 (da)
EP (2) EP1734995B1 (da)
JP (2) JP4594381B2 (da)
KR (1) KR101072736B1 (da)
CN (1) CN1964738A (da)
AT (1) ATE473760T1 (da)
AU (1) AU2004319276C1 (da)
BR (1) BRPI0418745A (da)
CA (1) CA2563080C (da)
CR (1) CR8698A (da)
CY (1) CY1110783T1 (da)
DE (1) DE602004028168D1 (da)
DK (1) DK1734995T3 (da)
ES (1) ES2346886T3 (da)
HK (1) HK1094167A1 (da)
HR (1) HRP20100521T1 (da)
IL (1) IL178474A (da)
MX (1) MXPA06011822A (da)
NO (1) NO20065227L (da)
NZ (1) NZ550324A (da)
PL (1) PL1734995T3 (da)
PT (1) PT1734995E (da)
RU (1) RU2361879C2 (da)
SI (1) SI1734995T1 (da)
WO (1) WO2005107800A1 (da)
ZA (1) ZA200609407B (da)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040208876A1 (en) * 2003-04-18 2004-10-21 Kim Kyung Jin Monoclonal antibodies to hepatocyte growth factor
PL1648998T3 (pl) * 2003-07-18 2015-03-31 Amgen Inc Specyficzne czynniki wiążące czynnik wzrostu hepatocytów
CN104804095A (zh) * 2004-08-05 2015-07-29 健泰科生物技术公司 人源化抗c-met 拮抗剂
CA2607699A1 (en) * 2005-06-02 2006-12-07 Galaxy Biotech, Llc Methods of treating brain tumors with antibodies
JP5014143B2 (ja) 2005-10-14 2012-08-29 学校法人福岡大学 膵島移植における移植膵島障害抑制剤
BRPI0617664B8 (pt) 2005-10-21 2021-05-25 Chugai Pharmaceutical Co Ltd uso de um anticorpo que reconhece a il-6 para a produção de uma composição farmacêutica para tratar o enfarte do miocárdio ou suprimir a remodelagem ventricular esquerda depois do enfarte do miocárdio
AR057582A1 (es) 2005-11-15 2007-12-05 Nat Hospital Organization Agentes para suprimir la induccion de linfocitos t citotoxicos
WO2007061029A1 (ja) * 2005-11-25 2007-05-31 Keio University 前立腺癌治療剤
ES2685915T3 (es) 2006-01-27 2018-10-15 Keio University Agentes terapéuticos para enfermedades que implican neovascularización coroidea
AR059922A1 (es) * 2006-04-01 2008-05-07 Galaxy Biotech Llc Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos
EP2025346B1 (en) 2006-04-07 2016-08-10 Osaka University Muscle regeneration promoter
BRPI0712222B1 (pt) 2006-06-02 2021-10-13 Aveo Pharmaceuticals, Inc. Proteína de ligação isolada que se liga ao fator de crescimento de hepatócito humano (hgf), seu uso e método de produção, ácido nucléico, vetor de expressão, célula hospedeira, e métodos para produzir um polipeptídeo que compreende uma região variável da cadeia pesada de imunoglobulina e para produzir um polipeptídeo que compreende uma região variável da cadeia leve de imunoglobulina
KR101196184B1 (ko) * 2006-06-02 2012-11-01 아베오 파마슈티컬즈, 인크. 간세포 성장 인자 (ｈｇｆ) 결합 단백질
WO2008090901A1 (ja) 2007-01-23 2008-07-31 Shinshu University 慢性拒絶反応抑制剤
CA2692165A1 (en) * 2007-06-25 2008-12-31 Amgen Inc. Compositions of specific binding agents to hepatocyte growth factor
PE20091827A1 (es) * 2008-04-11 2009-11-20 Galaxy Biotech Llc Combinacion del inhibidor hgf y el inhibidor egf para el tratamiento del cancer
CA2723617A1 (en) * 2008-05-14 2009-11-19 Amgen Inc. Combinations vegf(r) inhibitors and hepatocyte growth factor (c-met) inhibitors for the treatment of cancer
EP2305306B1 (en) 2008-06-05 2016-02-10 National Cancer Center Neuroinvasion inhibitor
PA8849001A1 (es) * 2008-11-21 2010-06-28 Lilly Co Eli Anticuerpos de c-met
US8545839B2 (en) * 2008-12-02 2013-10-01 Pierre Fabre Medicament Anti-c-Met antibody
WO2010119991A2 (en) 2009-04-17 2010-10-21 Takeda Pharmaceutical Company Limited Novel method of treating cancer
CN101555912B (zh) * 2009-04-29 2012-10-03 深圳市特辰科技股份有限公司 一种转轮式自锁安全制动装置及其工作方法
EP2287197A1 (en) * 2009-08-21 2011-02-23 Pierre Fabre Medicament Anti-cMET antibody and its use for the detection and the diagnosis of cancer
JP6051049B2 (ja) 2010-05-28 2016-12-21 中外製薬株式会社 抗腫瘍ｔ細胞応答増強剤
US20130315895A1 (en) 2010-07-01 2013-11-28 Takeda Pharmaceutical Company Limited COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET
CN103391773A (zh) 2010-09-27 2013-11-13 埃克塞里艾克西斯公司 用于治疗去势抵抗性前列腺癌和成骨性骨转移的met和vegf的双重抑制剂
CA2835242A1 (en) 2011-06-30 2013-01-03 Genentech, Inc. Anti-c-met antibody formulations
CZ2011514A3 (cs) * 2011-08-19 2013-01-23 Invos, Spol. S R. O. Biokontejner pro sber bioodpadu a komunálního odpadu
MX2014002762A (es) 2011-09-09 2014-07-30 Amgen Inc Uso de proteina c-met para predecir la eficacia de anticuerpos de factor de crecimiento de anti-hepatocitos (hgf) en pacientes con cancer esofagico y gastrico.
US9201074B2 (en) 2011-09-20 2015-12-01 Eli Lilly And Company Anti-c-Met antibodies
EP2873422A4 (en) 2012-07-10 2015-12-30 Takeda Pharmaceutical PHARMACEUTICAL PREPARATION FOR INJECTION
US9931400B2 (en) 2012-09-12 2018-04-03 Samsung Electronics Co., Ltd. Method of combination therapy for prevention or treatment of c-Met or angiogenesis factor induced diseases
JP2016516052A (ja) * 2013-03-14 2016-06-02 アルダー・バイオファーマシューティカルズ・インコーポレーテッド Ｈｇｆに対する抗体及びそれらを含む組成物
US9481725B2 (en) 2013-03-14 2016-11-01 Alderbio Holdings, Llc Antibodies to HGF and compositions containing
WO2015031578A1 (en) * 2013-08-28 2015-03-05 Abbvie Inc. Hgf assay
WO2018203545A1 (ja) 2017-05-02 2018-11-08 国立研究開発法人国立精神・神経医療研究センター Ｉｌ－６及び好中球の関連する疾患の治療効果の予測及び判定方法
US11692037B2 (en) 2017-10-20 2023-07-04 Hyogo College Of Medicine Anti-IL-6 receptor antibody-containing medicinal composition for preventing post-surgical adhesion

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US722041A (en) * 1902-11-24 1903-03-03 Mail Belting Company Conveyer-belt.
JP2564486B2 (ja) 1986-07-14 1996-12-18 修治 橋本 肝細胞増殖因子
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2 Inc Geänderte antikörper.
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
SG48759A1 (en) 1990-01-12 2002-07-23 Abgenix Inc Generation of xenogenic antibodies
GB9003621D0 (en) 1990-02-16 1990-04-11 Imp Cancer Res Tech Protein factor
GB9009548D0 (en) * 1990-04-27 1990-06-20 Celltech Ltd Chimeric antibody and method
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
ATE185601T1 (de) 1990-07-10 1999-10-15 Cambridge Antibody Tech Verfahren zur herstellung von spezifischen bindungspaargliedern
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
JP4124480B2 (ja) 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド 免疫グロブリン変異体
EP0746609A4 (en) 1991-12-17 1997-12-17 Genpharm Int NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES
US6498144B1 (en) 1993-10-18 2002-12-24 North Shore - Long Island Jewish Research Institute Use of scatter factor to enhance angiogenesis
US5837676A (en) 1993-10-18 1998-11-17 Long Island Jewish Medical Center Use of scatter factor to enhance angiogenesis
US5707624A (en) 1994-06-03 1998-01-13 The Regents Of The University Of Michigan Treatment of Kaposi's sarcoma by inhibition of scatter factor
US6214344B1 (en) * 1995-06-02 2001-04-10 Genetech, Inc. Hepatocyte growth factor receptor antagonists and uses thereof
US5686292A (en) 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
US5646036A (en) 1995-06-02 1997-07-08 Genentech, Inc. Nucleic acids encoding hepatocyte growth factor receptor antagonist antibodies
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
IL127558A0 (en) 1996-07-03 1999-10-28 Genentech Inc Hepatocyte growth factor receptor agonists and uses thereof
WO2000012560A1 (en) 1998-08-28 2000-03-09 Dendreon Corporation Selective apoptosis of neoplastic cells by an hla-dr specific monoclonal antibody
WO2001034650A1 (en) 1999-11-09 2001-05-17 The Government Of The United States Of America, As Represented By The Secretary, Department Of Heatlh And Human Services Hgf-sf monoclonal antibody combinations
JP2004536605A (ja) 2001-07-26 2004-12-09 イーライ・リリー・アンド・カンパニー インターロイキン１β抗体
JP2005527488A (ja) 2001-12-27 2005-09-15 バン アンデル リサーチ インスティチュート Ｍｅｔを発現し、肝細胞増殖因子と結合する腫瘍のモノクローナル抗体画像化および治療
WO2004019991A2 (en) 2002-08-30 2004-03-11 F. Hoffmann-La Roche Ag Scatter factor/hepatocyte growth factor antagonist nk4 for the treatment of glioma
US20040208876A1 (en) 2003-04-18 2004-10-21 Kim Kyung Jin Monoclonal antibodies to hepatocyte growth factor
US7220410B2 (en) 2003-04-18 2007-05-22 Galaxy Biotech, Llc Monoclonal antibodies to hepatocyte growth factor
ES2323425T3 (es) 2003-06-06 2009-07-15 Genentech, Inc. Modulacion de la interaccion entre la cadena beta de hgf y c-met.
EP1648493B1 (en) 2003-07-07 2009-12-09 Van Andel Research Institute Inhibition of tumor angiogenesis by combination of thrombospondin-1 and inhibitors of vascular endothelial growth factor
PL1648998T3 (pl) * 2003-07-18 2015-03-31 Amgen Inc Specyficzne czynniki wiążące czynnik wzrostu hepatocytów
KR100556660B1 (ko) 2003-11-11 2006-03-10 국립암센터 Ｈｇｆ의 중화가능 에피토프 및 이에 결합하는 중화 항체
CA2607699A1 (en) 2005-06-02 2006-12-07 Galaxy Biotech, Llc Methods of treating brain tumors with antibodies
AR059922A1 (es) * 2006-04-01 2008-05-07 Galaxy Biotech Llc Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos

Also Published As

Publication number Publication date
US7494650B2 (en) 2009-02-24
AU2004319276A1 (en) 2005-11-17
DK1734995T3 (da) 2010-10-25
NO20065227L (no) 2007-01-10
RU2006140257A (ru) 2008-05-20
DE602004028168D1 (de) 2010-08-26
ZA200609407B (en) 2008-07-30
RU2361879C2 (ru) 2009-07-20
AU2004319276B2 (en) 2010-08-26
WO2005107800A1 (en) 2005-11-17
US20040208876A1 (en) 2004-10-21
EP1734995A4 (en) 2007-04-25
SI1734995T1 (sl) 2010-09-30
MXPA06011822A (es) 2007-03-23
US7687063B2 (en) 2010-03-30
EP1734995B1 (en) 2010-07-14
BRPI0418745A (pt) 2007-12-11
ES2346886T3 (es) 2010-10-21
KR101072736B1 (ko) 2011-10-11
CY1110783T1 (el) 2015-06-10
PL1734995T3 (pl) 2010-12-31
IL178474A (en) 2011-04-28
JP4594381B2 (ja) 2010-12-08
JP2007532643A (ja) 2007-11-15
JP2011012067A (ja) 2011-01-20
CA2563080A1 (en) 2005-11-17
EP2204191A1 (en) 2010-07-07
HK1094167A1 (en) 2007-03-23
AU2004319276C1 (en) 2011-03-03
EP1734995A1 (en) 2006-12-27
CA2563080C (en) 2015-01-27
CR8698A (es) 2007-12-17
US20080019966A1 (en) 2008-01-24
NZ550324A (en) 2009-12-24
CN1964738A (zh) 2007-05-16
ATE473760T1 (de) 2010-07-15
US20120064066A1 (en) 2012-03-15
US20070160613A1 (en) 2007-07-12
US20090104192A1 (en) 2009-04-23
IL178474A0 (en) 2007-02-11
PT1734995E (pt) 2010-08-18
KR20070012711A (ko) 2007-01-26

Similar Documents

Publication Publication Date Title
HRP20100521T1 (hr) Monoklonska antitijela protiv čimbenika rasta hepatocita
RU2504551C2 (ru) Белки, связывающие антиген фактор роста, подобный гепаринсвязывающему эпидермальному фактору роста
HRP20210393T1 (hr) Anti-tfr antitijela i njihova uporaba u liječenju proliferativnih i upalnih poremećaja
TWI549968B (zh) 抗體-藥物共軛體
JP6325527B2 (ja) ヒト化ｐａｎ−ｈｅｒ抗体組成物
CN104136042B (zh) 使用抗假单胞菌Psl和PcrV结合分子的联合治疗
HRP20151019T1 (hr) PROTUTIJELA PROTIV c-MET
KR20160047567A (ko) 조작된 항-dll3 접합체 및 사용 방법
TW201834695A (zh) 共軛生物分子、醫藥組成物及方法
JP2018534933A5 (da)
EA200101064A1 (ru) Лечение раковых заболеваний путем комбинированного введения доцетаксела с рекомбинантными гуманизированными моноклональными анти-her2 антителами
MY145042A (en) Humanized monoclonal antibodies to hepatocyte growth factor
UA90457C2 (ru) Человеческое моноклональное антитело, которое специфически связывается с м-csf человека и блокирует связывание м-csf с с-fms
HRP20160494T4 (hr) Antigen-vezujući proteini za proproteinsku konvertazu subtilizin keksin tipa 9 (pcsk9)
CN106536562A (zh) 来那度胺或泊利度胺与经抗CD38抗体灭毒的干扰素α构筑体的组合，和其用途
HRP20221471T1 (hr) Protutijela anti-fgfr3 i postupci za njihovu uporabu
HRP20110599T1 (hr) Antitijela protiv toksina clostridium difficile i njihove primjene
RU2009110102A (ru) Лечение опухолей с помощью антитела к vegf
HRP20190008T4 (hr) Prevencija i liječenje sinukleinopatske i amiloidogene bolesti
AU2016364853A1 (en) Novel anti-claudin antibodies and methods of use
CN107001454A (zh) 新的抗mfi2抗体和使用方法
JP2016094424A5 (da)
JP2010520290A5 (da)
JP2020522280A5 (da)
JP2020522281A5 (da)